{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:45:31Z","timestamp":1791254731183,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"PATH\u2013Malaria Vaccine Initiative"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GlaxoSmithKline Biologicals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A previous RTS,S\/AS01B vaccine challenge trial demonstrated that a 3-dose (0-1-7\u2013month) regimen with a fractional third dose can produce high vaccine efficacy (VE) in adults challenged 3 weeks after vaccination. This study explored the VE of different delayed fractional dose regimens of adult and pediatric RTS,S\/AS01 formulations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 130 participants were randomized into 5 groups. Four groups received 3 doses of RTS,S\/AS01B or RTS,S\/AS01E on a 0-1-7\u2013month schedule, with the final 1 or 2 doses being fractional (one-fifth dose volume). One group received 1 full (month 0) and 1 fractional (month 7) dose of RTS,S\/AS01E. Immunized and unvaccinated control participants underwent Plasmodium falciparum\u2013infected mosquito challenge (controlled human malaria infection) 3 months after immunization, a timing chosen to potentially discriminate VEs between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The VE of 3-dose formulations ranged from 55% (95% confidence interval, 27%\u201372%) to 76% (48%\u201389%). Groups administered equivalent formulations of RTS,S\/AS01E and RTS,S\/AS01B demonstrated comparable VE. The 2-dose group demonstrated lower VE (29% [95% confidence interval, 6%\u201346%]). All regimens were well tolerated and immunogenic, with trends toward higher anti-circumsporozoite antibody titers in participants protected against infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>RTS,S\/AS01E can provide VE comparable to an equivalent RTS,S\/AS01B regimen in adults, suggesting a universal formulation may be considered. Results also suggest that the 2-dose regimen is inferior to the 3-dose regimens evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>NCT03162614<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa421","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T19:09:42Z","timestamp":1595012982000},"page":"1681-1691","source":"Crossref","is-referenced-by-count":42,"title":["A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S\/AS01E and RTS,S\/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults"],"prefix":"10.1093","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9274-4554","authenticated-orcid":false,"given":"James E","family":"Moon","sequence":"first","affiliation":[{"name":"Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ockenhouse","sequence":"additional","affiliation":[{"name":"PATH\u2013Malaria Vaccine Initiative, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Regules","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Lee","sequence":"additional","affiliation":[{"name":"PATH\u2013Malaria Vaccine Initiative, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilin","family":"Chuang","sequence":"additional","affiliation":[{"name":"Naval Medical Research Center, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Traskine","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Jongert","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ivinson","sequence":"additional","affiliation":[{"name":"PATH\u2013Malaria Vaccine Initiative, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Morelle","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack L","family":"Komisar","sequence":"additional","affiliation":[{"name":"Naval Medical Research Center, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lievens","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sedegah","sequence":"additional","affiliation":[{"name":"Naval Medical Research Center, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey S","family":"Garver","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K","family":"Sikaffy","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman C","family":"Waters","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Ripley","family":"Ballou","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opokua","family":"Ofori-Anyinam","sequence":"additional","affiliation":[{"name":"GSK Biologicals, Rixensart, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"RTS,S Malaria Vaccine Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B","family":"Cicatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin T","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J","family":"Cowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele D","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanial K","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viseth","family":"Ngauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige E","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack N","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kooken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Leprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B","family":"Cicatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin T","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J","family":"Cowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele D","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanial K","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viseth","family":"Ngauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M","family":"Tosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige E","family":"Waterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack N","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kooken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lia","family":"Leprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"2020101307145176400_CIT0001","volume-title":"2013 Update to the Malaria Vaccine Technology Roadmap","author":"World Health Organization\u2013Malaria Vaccine Funders Group","year":"2013"},{"key":"2020101307145176400_CIT0002","doi-asserted-by":"crossref","first-page":"e1002456","DOI":"10.1371\/journal.pmed.1002456","article-title":"malERA: an updated research agenda for malaria elimination and eradication","volume":"14","author":"Rabinovich","year":"2017","journal-title":"PLoS Med"},{"key":"2020101307145176400_CIT0003","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"RTS,S Clinical Trials Partnership","year":"2014","journal-title":"PLoS Med"},{"key":"2020101307145176400_CIT0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","journal-title":"Lancet"},{"key":"2020101307145176400_CIT0005","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"RTS,S Clinical Trials Partnership","year":"2011","journal-title":"N Engl J Med"},{"key":"2020101307145176400_CIT0006","author":"ClinicalTrials.gov"},{"key":"2020101307145176400_CIT0007","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12936-017-1841-9","article-title":"Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine","volume":"16","author":"Greenwood","year":"2017","journal-title":"Malar J"},{"key":"2020101307145176400_CIT0008","author":"World Health Organization"},{"key":"2020101307145176400_CIT0009","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1016\/j.vaccine.2015.09.093","article-title":"Recent advances in recombinant protein-based malaria vaccines","volume":"33","author":"Draper","year":"2015","journal-title":"Vaccine"},{"key":"2020101307145176400_CIT0010","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/j.amepre.2015.09.011","article-title":"The march toward malaria vaccines","volume":"49","author":"Hoffman","year":"2015","journal-title":"Am J Prev Med"},{"key":"2020101307145176400_CIT0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7205\/MILMED.170.4S.12","article-title":"History of U.S. military contributions to the study of malaria","volume":"170","author":"Ockenhouse","year":"2005","journal-title":"Mil Med"},{"key":"2020101307145176400_CIT0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"RTS,S Malaria Vaccine Evaluation Group. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"2020101307145176400_CIT0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"key":"2020101307145176400_CIT0014","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"2020101307145176400_CIT0015","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa020534","article-title":"Clinical responses to undiluted and diluted smallpox vaccine","volume":"346","author":"Frey","year":"2002","journal-title":"N Engl J Med"},{"key":"2020101307145176400_CIT0016","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa043540","article-title":"Dose sparing with intradermal injection of influenza vaccine","volume":"351","author":"Kenney","year":"2004","journal-title":"N Engl J Med"},{"key":"2020101307145176400_CIT0017","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14760584.2.2.231","article-title":"Development of RTS,S\/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant","volume":"2","author":"Gar\u00e7on","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"2020101307145176400_CIT0018","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/09680519060120050701","article-title":"TLR4 agonists as immunomodulatory agents","volume":"12","author":"Alderson","year":"2006","journal-title":"J Endotoxin Res"},{"key":"2020101307145176400_CIT0019","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/13543784.7.9.1475","article-title":"QS-21: a water-soluble triterpene glycoside adjuvant","volume":"7","author":"Kensil","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"2020101307145176400_CIT0020","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"key":"2020101307145176400_CIT0021","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","article-title":"Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component","volume":"6","author":"Tamminga","year":"2011","journal-title":"PLoS One"},{"key":"2020101307145176400_CIT0022","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/1475-2875-11-384","article-title":"Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum","volume":"11","author":"Clement","year":"2012","journal-title":"Malar J"},{"key":"2020101307145176400_CIT0023","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2008.02.048","article-title":"Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S\/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research","volume":"26","author":"Kester","year":"2008","journal-title":"Vaccine"},{"key":"2020101307145176400_CIT0024","doi-asserted-by":"crossref","first-page":"e0131571","DOI":"10.1371\/journal.pone.0131571","article-title":"Ad35.CS.01-RTS,S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-na\u00efve adults","volume":"10","author":"Ockenhouse","year":"2015","journal-title":"PLoS One"},{"key":"2020101307145176400_CIT0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12936-015-0605-7","article-title":"The effect of immunization schedule with the malaria vaccine candidate RTS,S\/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants","volume":"14","author":"Ajua","year":"2015","journal-title":"Malar J"},{"key":"2020101307145176400_CIT0026","doi-asserted-by":"crossref","first-page":"e115126","DOI":"10.1371\/journal.pone.0115126","article-title":"Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S\/AS01E in young children","volume":"9","author":"Olotu","year":"2014","journal-title":"PLoS One"},{"key":"2020101307145176400_CIT0027","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy","volume":"10","author":"Doba\u00f1o","year":"2019","journal-title":"Nat Commun"},{"key":"2020101307145176400_CIT0028","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa421\/33805574\/jiaa421.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/10\/1681\/33873015\/jiaa421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/10\/1681\/33873015\/jiaa421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T11:20:57Z","timestamp":1602588057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/10\/1681\/5873826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,20]]},"published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa421","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,15]]},"published":{"date-parts":[[2020,7,20]]}}}